Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control Study
2011

NSAIDs and Prostate Cancer Risk

Sample size: 9007 publication 10 minutes Evidence: moderate

Author Information

Author(s): Mahmud Salaheddin M., Franco Eduardo L., Turner Donna, Platt Robert W., Beck Patricia, Skarsgard David, Tonita Jon, Aprikian Armen G.

Primary Institution: McGill University

Hypothesis

Do non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of prostate cancer?

Conclusion

The study suggests that using certain NSAIDs, particularly propionates, may modestly reduce the risk of prostate cancer.

Supporting Evidence

  • Any use of propionates was associated with a modest reduction in prostate cancer risk.
  • Aspirin use did not show a significant inverse association with prostate cancer risk.
  • Most cases were older than 65 years at diagnosis.

Takeaway

Taking some pain relievers called NSAIDs might help lower the chances of getting prostate cancer, but not all types work the same way.

Methodology

A nested case-control study using data from Saskatchewan Prescription Drug Plan and Cancer Registry to analyze NSAID use and prostate cancer risk.

Potential Biases

Potential for differential misclassification due to screening practices among NSAID users.

Limitations

The study lacked information on over-the-counter NSAID use and PSA testing, which could affect the results.

Participant Demographics

Men aged 40 years or older diagnosed with prostate cancer between 1985 and 2000.

Statistical Information

P-Value

p<0.001

Confidence Interval

95%CI 0.84-0.95

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016412

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication